WHO drug information. Vol. 28 No. 1 2014. / by World Health Organization.

Format:

Book

Author/Creator:

World Health Organization, author.

Language:

English

Subjects (All):

Drugs--Standards--Periodicals.

Drugs.

Pharmaceutical industry--Periodicals.

Pharmaceutical industry.

Physical Description:

1 online resource (124 p.)

Place of Publication:

London, England : World Health Organization, [2014]

Summary:

WHO Drug Information communicates pharmaceutical information that is either developed and issued by WHO or transmitted to WHO by research and regulatory agencies throughout the World. The journal also includes regular presentations of newly proposed and recommended International Nonproprietary Names (INN) for Pharmaceuticals Substances. This volume contains the recommended INN List No. 71.

Contents:

""Cover""; ""Cover""; ""Contents""; ""Contents""; ""Regulatory harmonization""; ""Regulatory harmonization""; ""The International Generic Drug Regulators Pilot""; ""The International Generic Drug Regulators Pilot""; ""Introduction""; ""Introduction""; ""Exploratory meeting""; ""Exploratory meeting""; ""Preliminary surveys""; ""Preliminary surveys""; ""The path forward""; ""The path forward""; ""Operating procedures""; ""Operating procedures""; ""Progress to date""; ""Progress to date""; ""Decentralised Procedure as a model for cooperation""

""Decentralised Procedure as a model for cooperation""""Some observations""; ""Some observations""; ""Conclusion""; ""Conclusion""; ""References""; ""References""; ""WHO support for medicines regulatory harmonization in Africa: focus on East African Community""; ""WHO support for medicines regulatory harmonization in Africa: focus on East African Community""; ""The African Medicines Registration Harmonization initiative""; ""The African Medicines Registration Harmonization initiative""; ""The role of Regional Economic Communities""; ""The role of Regional Economic Communities""

""The EAC Medicines Registration Harmonization project""""The EAC Medicines Registration Harmonization project""; ""NMRA assessments""; ""NMRA assessments""; ""Progress towards harmonized registration""; ""Progress towards harmonized registration""; ""Collaboration with other initiatives""; ""Collaboration with other initiatives""; ""Conclusion""; ""Conclusion""; ""References""; ""References""; ""Technologies, standards and norms""; ""Technologies, standards and norms""; ""Standards for biological products""; ""Standards for biological products""; ""Biotherapeutic products""

""Biotherapeutic products""""Adjuvanted vaccines""; ""Adjuvanted vaccines""; ""Typhoid conjugate vaccines""; ""Typhoid conjugate vaccines""; ""Reference preparations""; ""Reference preparations""; ""References""; ""References""; ""Safety and efficacy issues""; ""Safety and efficacy issues""; ""Combined hormonal contraceptives and venous thromboembolism""; ""Combined hormonal contraceptives and venous thromboembolism""; ""Clobazam: serious skin reactions""; ""Clobazam: serious skin reactions""; ""Amiodarone: pulmonary toxicity""; ""Amiodarone: pulmonary toxicity""

""Methylphenidate: rare risk of long-lasting erections in males""""Methylphenidate: rare risk of long-lasting erections in males""; ""Glibenclamide: risk of hypoglycaemia in elderly and renal-impaired patients""; ""Glibenclamide: risk of hypoglycaemia in elderly and renal-impaired patients""; ""Subcutaneous epoetin alfa: contraindicated in Singapore in chronic kidney disease patients""; ""Subcutaneous epoetin alfa: contraindicated in Singapore in chronic kidney disease patients""; ""Acipimox: only to be used as additional or alternative treatment""

""Acipimox: only to be used as additional or alternative treatment""

Notes:

Description based upon print version of record.

Description based on print version record.

ISBN:

92-4-069285-1

OCLC:

888748998